Johnson & Johnson (JNJ) Stock Analysis
Johnson & Johnson is a diversified healthcare conglomerate operating in pharmaceutical innovation and medical devices, making it one of the largest healthcare companies globally. Investors research JNJ for its dual revenue streams, established market position, and dividend history, though valuation and patent cliff risks warrant careful consideration.
Get a full AI research report on JNJ
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Johnson & Johnson do?
JNJ operates two primary segments: Innovative Medicine, which develops and sells prescription pharmaceuticals across oncology, immunology, neuroscience, and infectious diseases; and MedTech, which manufactures surgical instruments, orthopedic devices, cardiovascular products, and vision-care solutions. Revenue flows through hospitals, healthcare professionals, wholesalers, and retailers worldwide. The company's model relies on continuous R&D to maintain a pipeline of new drugs and devices while defending existing market share.
Bull case
- ✓Diversified revenue across two segments reduces dependence on any single therapeutic area or product category, providing structural stability.
- ✓Gross margin of 68% and operating margin of 28.6% demonstrate strong pricing power and operational efficiency in a competitive healthcare market.
- ✓Forward P/E of 19.7x is materially lower than trailing P/E of 29.0x, suggesting market expectations for earnings growth in coming years.
- ✓Dividend yield of 2.14% with a 60.8% payout ratio leaves room for dividend growth while maintaining financial flexibility.
- ✓Established distribution networks and brand recognition in both pharmaceuticals and medical devices create barriers to entry for competitors.
Bear case
- ✗Trailing P/E of 29.0x sits above historical averages for the healthcare sector, reflecting premium valuation that leaves limited margin for disappointment.
- ✗Debt-to-equity ratio of 67.73% is elevated, constraining financial flexibility and increasing refinancing risk in a rising-rate environment.
- ✗PEG ratio of 4.88 suggests the stock may be priced at a premium relative to expected earnings growth, raising questions about value at current levels.
- ✗Patent expirations on key drugs create ongoing revenue headwinds that require successful new product launches to offset.
- ✗Regulatory and litigation risks in pharmaceuticals and medical devices remain persistent industry-wide challenges that could impact profitability.
JNJ valuation & financial health
Johnson & Johnson trades at a trailing P/E of 29.0x with a forward P/E of 19.7x, indicating the market is pricing in meaningful earnings growth ahead. The company's 68% gross margin and 28.6% operating margin reflect strong operational leverage and pricing discipline. However, the elevated debt-to-equity ratio of 67.73% and PEG ratio of 4.88 suggest the current valuation embeds significant growth expectations. Net profit margin of 21.5% demonstrates solid bottom-line conversion, while the 60.8% dividend payout ratio indicates sustainable income distribution with retained earnings for reinvestment.
The bottom line
Johnson & Johnson presents a classic tension between quality and valuation. The company's diversified business model, strong margins, and market position appeal to investors seeking healthcare exposure, yet the elevated trailing P/E and PEG ratio warrant careful consideration of entry points. Key factors to weigh include the company's ability to execute on pipeline launches to justify forward earnings estimates, the trajectory of debt reduction, and how patent cliff impacts unfold. Investors should monitor quarterly earnings growth, R&D productivity, and debt management as indicators of whether current valuation remains justified.
Frequently asked questions
What does Johnson & Johnson do?
JNJ operates in two main areas: Innovative Medicine (prescription pharmaceuticals for oncology, immunology, neuroscience, and other therapeutic areas) and MedTech (surgical instruments, orthopedic devices, cardiovascular products, and vision-care solutions). The company sells these products globally to hospitals, healthcare professionals, wholesalers, and retailers.
Is Johnson & Johnson overvalued?
JNJ's trailing P/E of 29.0x is elevated relative to historical healthcare sector averages, though the forward P/E of 19.7x suggests the market expects earnings growth. The PEG ratio of 4.88 indicates valuation at a premium to growth expectations, which investors should weigh against the company's market position and dividend stability.
What are Johnson & Johnson's main risks?
Key risks include patent expirations on major drugs, elevated debt levels (debt-to-equity of 67.73%), regulatory and litigation exposure inherent in pharmaceuticals, and the need for successful new product launches to offset revenue declines from generic competition.
Does Johnson & Johnson pay a dividend?
Yes, JNJ pays a dividend with a yield of 2.14% and a payout ratio of 60.8%, indicating the company distributes a meaningful portion of earnings while retaining capital for reinvestment and debt management.
How profitable is Johnson & Johnson?
JNJ demonstrates strong profitability with a gross margin of 68%, operating margin of 28.6%, and net profit margin of 21.5%, reflecting operational efficiency and pricing power in both pharmaceuticals and medical devices.
What is Johnson & Johnson's debt situation?
JNJ carries a debt-to-equity ratio of 67.73%, which is elevated and may limit financial flexibility in a rising-rate environment, though the company's strong cash generation typically supports debt service and dividend payments.
Research JNJ with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.